Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Payables (2020 - 2025)

SAB Biotherapeutics' Payables history spans 6 years, with the latest figure at $6.6 million for Q4 2025.

  • For Q4 2025, Payables rose 234.12% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $6.6 million, up 234.12%, while the annual FY2025 figure was $6.6 million, 234.12% up from the prior year.
  • Payables reached $6.6 million in Q4 2025 per SABSW's latest filing, up from $3.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $12.9 million in Q1 2022 to a low of $1.3 million in Q3 2024.
  • Average Payables over 5 years is $4.0 million, with a median of $2.6 million recorded in 2025.
  • Peak YoY movement for Payables: tumbled 85.35% in 2023, then surged 234.12% in 2025.
  • A 5-year view of Payables shows it stood at $6.3 million in 2021, then fell by 28.83% to $4.5 million in 2022, then tumbled by 55.15% to $2.0 million in 2023, then dropped by 1.31% to $2.0 million in 2024, then soared by 234.12% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Payables are $6.6 million (Q4 2025), $3.0 million (Q3 2025), and $2.6 million (Q2 2025).